An observational study in Pneumonia and Respiratory Failure, sponsored by Evangelismos Hospital. Recruiting at 2 sites in Greece. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-06.
Sponsored by Evangelismos Hospital · Observational
the study compares two non-invasive respiratory support modalities ie CPAP and High Flow nasal cannula oxygen for the treatment of severe hypoxemic respiratory failure attributed to Community acquired Pneumonia.
CPAP and High Flow nasal cannula oxygen are two established modalities for non-invasive respiratory support . In COVID pandemic era both CPAP and HFNO were widely used in the ward for the treatment of COVID-19 induced acute hypoxemic respiratory failure in order to prevent progression to intubation. Head to head comparison between the two modalities mentioned for the treatment of severe hypoxemic respiratory failure is not available neither in COVID pneumonia or Community acquired pneumonia (CAP).
1,564 studies on the registry are indexed under Pneumonia; 265 are open to participants now.
This study's planned enrollment of 100 is below the median of 252 across 535 observational studies indexed under Pneumonia.
Browse Pneumonia studies →Evangelismos Hospital is the lead sponsor of 29 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult Patients with community acquired pneumonia induced acute hypoxemic respiratory failure that are hospitalized in the common ward and need FiO2 >50% to keep SpO2 >93%, or SpO2 >95% in case of persistent respiratory distress defined as RR>35/min.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
When a patient needs FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min, full face CPAP will be applied
Device: CPAP
When a patient needs FiO2 \>50% to keep SpO2 \>93%, or SpO2 \>95% in case of persistent respiratory distress defined as RR\>35/min, HFNO will be applied
Device: HFNO
CPAP will be delivered with a CPAP valve with venturi flow system with full-face mask. Treatment will start with CPAP set at 10cmH2O and FiO2 60% to target a SpO2 ≥90% or PO2 ≥60mmHg and then adjusted according to SpO2, respiratory distress and clinical tolerance
HFNO will be applied initially at maximal settings: 100% FiO2, flow rate 60 L/min and temperature 37C . Within 1 to 2 h, the HFNO settings should be titrated based on patients respiratory rate (\<25-30 per minute), SpO2 (92-96%) and comfort
days free from ventilatory support
days without support with either mechanical ventilation, HFNO, CPAP
Time frame: 28 days
treatment failure defined
no of patients that needed intubation and invasive mechanical ventilation or died
Time frame: 28 days
intubation rate
Time frame: 28 days
hospital mortality
Time frame: 28 days
days under non-invasive respiratory support
days without support with HFNO or CPAP
Time frame: 28 days
hospital length of stay
Time frame: 28 days
Partial pressure of oxygen PaO2 change at 2h, 12h and 24h
Time frame: 28 days
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Evangelismos Hospital